Swiss-based, formerly Bruker AG - split on the 5th October 2001 into the groups: Bruker Daltonics (Mass spectroscopy), Bruker Optics (Infrared spectroscopy), Bruker AXS (X-ray spectroscopy) and Bruker BioSpin (The largest part, the NMR business core, the EPR and the Tomography activities).
Product Lines:

'CMC Contrast AB (Copenhagen Malmø Contrast AB) was established in April 2000. CMC Contrast AB was founded by professor Henrik Thomsen and the two main owners Malmøhus Invest AB and Öresund - Healthcare Capital KS.'
'The purpose of CMC Contrast AB is to develop the product CMC 001 to a registered medicinal product with market authorisation in the international pharmaceutical markets. CMC Contrast AB holds all the rights to CMC 001, and the company aims to develop CMC 001 to a registered medicinal product on a worldwide basis.'

Contrast agents are chemical substances introduced to the anatomical or functional region being imaged, to increase the differences between different tissues or between normal and abnormal tissue, by altering the relaxation times. MRI contrast agents are classified by the different changes in relaxation times after their injection.
The design objectives for the next generation of MR contrast agents will likely focus on prolonging intravascular retention, improving tissue targeting, and accessing new contrast mechanisms. Macromolecular paramagnetic contrast agents are being tested worldwide. Preclinical data shows that these agents demonstrate great promise for improving the quality of MR angiography, and in quantificating capillary permeability and myocardial perfusion.
Ultrasmall superparamagnetic iron oxide (USPIO) particles have been evaluated in multicenter clinical trials for lymph node MR imaging and MR angiography, with the clinical impact under discussion. In addition, a wide variety of vector and carrier molecules, including antibodies, peptides, proteins, polysaccharides, liposomes, and cells have been developed to deliver magnetic labels to specific sites. Technical advances in MR imaging will further increase the efficacy and necessity of tissue-specific MRI contrast agents.

See also Adverse Reaction and Nephrogenic Systemic Fibrosis.

See also the related poll result: 'The development of contrast agents in MRI is'

(PDWI) In density weighted imaging, the contrast is dependent on the density of protons in the tissue. Proton density weighted images are generated by choosing TR greater than T1 (typically ≥ 2 000 ms) and TE less than T2 (typically ≤ 30 ms), the two exponential terms are both close to one and therefore M is relatively independent of T1 and T2, thereby emphasizing Mxy0, which is proportional to the proton density. Also called (Rho) ρ-weighted.

See also Proton Density Weighted Image.

(DTI) Diffusion tensor imaging is the more sophisticated form of DWI, which allows for the determination of directionality as well as the magnitude of water diffusion. This kind of MR imaging can estimates damage to nerve fibers that connect the area of the brain affected by the stroke to brain regions that are distant from it, and can be used to determine the effectiveness of stroke prevention medications.
DTI (FiberTrak) enables to visualize white matter fibers in the brain and can map (trace image) subtle changes in the white matter associated with diseases such as multiple sclerosis and epilepsy, as well as assessing diseases where the brain's wiring is abnormal, such as schizophrenia.
The fractional anisotropy (FA) gives information about the shape of the diffusion tensor at each voxel. The FA is based on the normalized variance of the eigenvalues. The fractional anisotropy reflects differences between an isotropic diffusion and a linear diffusion. The FA range is between 0 and 1 (0 = isotropic diffusion, 1 = highly directional).
The development of new imaging methods and some useful analysis techniques, such as 3-dimensional anisotropy contrast (3DAC) and spatial tracking of the diffusion tensor tractography (DTT), are currently under study.